Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital.
Intern Emerg Med
October 2023
Arianna Foundation, Bologna, Italy.
Heparin-induced thrombocytopenia (HIT) is a rare immuno-mediated adverse reaction with high thrombotic and mortality risk. To evaluate incidence and outcomes of HIT cases diagnosed at a tertiary care hospital from 2007 to 2018. A retrospective study was conducted.
View Article and Find Full Text PDFA comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.
J Thromb Thrombolysis
August 2009
Department of Pharmacy and the Division of Hematology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Background And Objective: Heparin-Induced Thrombocytopenia (HIT), if left untreated, can lead to thrombocytopenia, thromboembolic complications and even death. Two thrombin inhibitors, lepirudin and argatroban, have been shown to improve clinical outcomes compared to historical controls in the management of HIT. The purpose of this retrospective study was to compare the effects of lepirudin and argatroban in the management of HIT.
View Article and Find Full Text PDFHeparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients.
Ann Thorac Surg
September 2007
Department of Surgery, Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, North Carolina 27703, USA.
Background: The presence of heparin-induced thrombocytopenia (HIT) increases the risk for thromboembolic events in ventricular assist device (VAD) patients undergoing transplantation. However, cardiopulmonary bypass with alternative anticoagulants is often complicated by bleeding. Owing to this concern, we compared outcomes of HIT-positive versus control bridge-to-transplantation VAD patients; both groups were reexposed to heparin for cardiopulmonary bypass during transplant.
View Article and Find Full Text PDFPharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.
Drugs Aging
March 1996
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Hirudin and its derivatives represent the first parenteral anticoagulants introduced since the discovery of heparin in the early 1900s. Hirudin, the naturally occurring anticoagulant of the leech, is a single peptide chain of 65 amino acids with a molecular weight of about 7000. Recombinant technology has developed methods to produce recombinant forms of hirudin (r-hirudin) in sufficient quantities for therapeutic use.
View Article and Find Full Text PDFExperience with antiheparin compounds in essential thrombocytopenic purpura.
Proc Staff Meet Mayo Clin
July 1948
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!